Home › Companies › BEAM THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BEAM THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2024: 3 items on BEAM THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024: 2 approved · 1 passed (calculated).
Notable dissent: 1 director (11.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BEAM THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are BEAM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Graham Cooper | 49,482,793 | 6,520,772 | 1,838,647 | -- | 8,424,668 | 88% | Passed (calculated) | — |
| 2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 | 66,048,930 | 176,166 | 41,784 | -- | -- | 99.7% | Approved | — |
| 3. Compensation of the Company's named executive officers | 56,501,513 | 1,295,311 | 45,388 | -- | 8,424,668 | 98% | Approved | — |
This meeting is also recorded here as June 6, 2024; both records come from the same filing, so the date should be checked against it.
Source: BEAM THERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
266 asset managers disclosed a vote on at least one BEAM THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominee as a Class I Director for a three-year term ending at our Annual Meeting of Stockholders to be held in 2027: Graham Cooper
BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Graham Cooper”): 49,482,793 for, 6,520,772 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 23,694,238 for, 1,048,788 against, 13,077 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 7,681,910 | 0 | 0 | 0 | For |
| Vanguard | 7,487,514 | 0 | 0 | 0 | For |
| Fidelity | 2,759,135 | 0 | 0 | 0 | For |
| BlackRock | 1,804,526 | 0 | 0 | 0 | For |
| State Street | 1,164,068 | 16,888 | 0 | 0 | For |
| T. Rowe Price | 1,005,154 | 0 | 0 | 0 | For |
| Charles Schwab | 580,439 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 211,109 | 0 | 0 | 0 | For |
| TIAA | 172,527 | 0 | 0 | 0 | For |
| Global X | 155,404 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 139,813 | 0 | 0 | Against |
| OLD WESTBURY FUNDS INC | 0 | 129,469 | 0 | 0 | Against |
| First Trust | 0 | 118,821 | 0 | 0 | Against |
| Equitable | 28,330 | 85,310 | 0 | 0 | Mixed |
| AMERICAN BEACON FUNDS | 111,525 | 0 | 0 | 0 | For |
| Dimensional | 0 | 100,098 | 0 | 0 | Against |
| Russell Investments | 95,459 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,199 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 79,885 | 0 | 0 | Against |
| American Century | 0 | 74,299 | 0 | 0 | Against |
| Lincoln Financial | 59,800 | 5,835 | 0 | 0 | Mixed |
| John Hancock | 36,100 | 27,300 | 0 | 0 | Mixed |
| ProShares | 0 | 54,921 | 0 | 0 | Against |
| Pacific Life | 50,287 | 0 | 0 | 0 | For |
| Morgan Stanley | 46,530 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: Approve, on an advisory basis, the compensation of our named executive officers.
BEAM THERAPEUTICS INC.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 56,501,513 for, 1,295,311 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 7,681,910 | 0 | 0 | 0 | For |
| Vanguard | 7,487,514 | 0 | 0 | 0 | For |
| Fidelity | 2,759,135 | 0 | 0 | 0 | For |
| BlackRock | 1,804,526 | 0 | 0 | 0 | For |
| State Street | 1,176,191 | 4,765 | 0 | 0 | For |
| T. Rowe Price | 1,005,154 | 0 | 0 | 0 | For |
| Charles Schwab | 580,439 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 211,109 | 0 | 0 | 0 | For |
| TIAA | 172,527 | 0 | 0 | 0 | For |
| Global X | 155,404 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 139,813 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 129,469 | 0 | 0 | 0 | For |
| First Trust | 118,821 | 0 | 0 | 0 | For |
| Equitable | 113,640 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 111,525 | 0 | 0 | 0 | For |
| Dimensional | 100,098 | 0 | 0 | 0 | For |
| Russell Investments | 95,459 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,199 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,885 | 0 | 0 | 0 | For |
| American Century | 0 | 74,299 | 0 | 0 | Against |
| Lincoln Financial | 65,635 | 0 | 0 | 0 | For |
| John Hancock | 63,400 | 0 | 0 | 0 | For |
| ProShares | 54,921 | 0 | 0 | 0 | For |
| Pacific Life | 50,287 | 0 | 0 | 0 | For |
| Morgan Stanley | 46,530 | 0 | 0 | 0 | For |
Fund voting reports, all 62 managers: 24,647,728 for, 95,270 against, 13,077 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 5,443,039 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 3,516,479 | 0 | 0 | 0 | For |
| Fidelity | 3,060,927 | 0 | 0 | 0 | For |
| State Street | 2,269,998 | 25,601 | 0 | 0 | For |
| BlackRock | 2,146,077 | 20,873 | 0 | 0 | For |
| Nikko Asset Management Americas, Inc. | 2,028,101 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,879,617 | 0 | 0 | 0 | For |
| Temasek Holdings (Private) Ltd | 1,812,972 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,273,512 | 0 | 0 | 0 | For |
| Impresa Management LLC | 1,139,443 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 872,600 | 0 | 0 | 0 | For |
| Charles Schwab | 580,550 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 505,100 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 446,964 | 0 | 0 | 0 | For |
| JPMorgan | 446,074 | 0 | 0 | 0 | For |
| Northern Trust | 372,313 | 49 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 329,950 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 273,115 | 0 | 0 | 0 | For |
| Vanguard | 197,592 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 190,474 | 0 | 0 | 0 | For |
| Nuveen | 174,191 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 143,748 | 0 | 0 | Against |
| Rafferty Asset Management, LLC | 139,813 | 0 | 0 | 0 | For |
| BESSEMER INVESTMENT MANAGEMENT LLC | 129,469 | 0 | 0 | 0 | For |
| UBS | 0 | 114,876 | 0 | 0 | Against |
Institutional-manager reports, all 221 managers: 30,758,500 for, 571,071 against, 90 abstained, 1,632 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.
BEAM THERAPEUTICS INC.’s own tally for this item (“2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024”): 66,048,930 for, 176,166 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 was ratified, based on the following votes:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 24,743,026 for, 13,077 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 7,681,910 | 0 | 0 | 0 | For |
| Vanguard | 7,487,514 | 0 | 0 | 0 | For |
| Fidelity | 2,759,135 | 0 | 0 | 0 | For |
| BlackRock | 1,804,526 | 0 | 0 | 0 | For |
| State Street | 1,180,956 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,005,154 | 0 | 0 | 0 | For |
| Charles Schwab | 580,439 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 211,109 | 0 | 0 | 0 | For |
| TIAA | 172,527 | 0 | 0 | 0 | For |
| Global X | 155,404 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 139,813 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 129,469 | 0 | 0 | 0 | For |
| First Trust | 118,821 | 0 | 0 | 0 | For |
| Equitable | 113,640 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 111,525 | 0 | 0 | 0 | For |
| Dimensional | 100,098 | 0 | 0 | 0 | For |
| Russell Investments | 95,459 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,199 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,885 | 0 | 0 | 0 | For |
| American Century | 74,299 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,635 | 0 | 0 | 0 | For |
| John Hancock | 63,400 | 0 | 0 | 0 | For |
| ProShares | 54,921 | 0 | 0 | 0 | For |
| Pacific Life | 50,287 | 0 | 0 | 0 | For |
| Morgan Stanley | 46,530 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,280,827 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARK ETF Trust | 9.34% |
| 2 | Vanguard | 9.10% |
| 3 | Fidelity | 3.35% |
| 4 | BlackRock | 2.19% |
| 5 | State Street | 1.44% |
| 6 | T. Rowe Price | 1.22% |
| 7 | Charles Schwab | 0.71% |
| 8 | Columbia Threadneedle | 0.26% |
| 9 | TIAA | 0.21% |
| 10 | Global X | 0.19% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARCH Venture Management, LLC | 6.62% |
| 2 | FARALLON CAPITAL MANAGEMENT LLC | 4.27% |
| 3 | Fidelity | 3.72% |
| 4 | State Street | 2.79% |
| 5 | BlackRock | 2.63% |
| 6 | Nikko Asset Management Americas, Inc. | 2.46% |
| 7 | Redmile Group, LLC | 2.28% |
| 8 | Temasek Holdings (Private) Ltd | 2.20% |
| 9 | T. Rowe Price | 1.55% |
| 10 | Impresa Management LLC | 1.38% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 11,692,853 | 14.21% | Form 13F, quarter ended March 31, 2024 |
| ARK Investment Management LLC | 9,393,889 | 11.42% | Schedule 13G, filed January 29, 2024 |
| Vanguard Group | 9,250,784 | 11.24% | Form 13F, quarter ended March 31, 2024 |
| FMR LLC and affiliates | 8,953,800 | 10.88% | Proxy statement (DEF 14A), proxy filed April 19, 2024 |
| BlackRock | 8,148,205 | 9.90% | Form 13F, quarter ended March 31, 2024 |
| Funds affiliated with ARCH Venture Partners | 5,443,039 | 6.62% | Proxy statement (DEF 14A), proxy filed April 19, 2024 |
| Farallon Capital Partners and affiliates | 4,105,753 | 4.99% | Proxy statement (DEF 14A), proxy filed April 19, 2024 |
| State Street | 3,731,192 | 4.53% | Form 13F, quarter ended March 31, 2024 |
| John Evans | 1,781,081 | 2.16% | Proxy statement (DEF 14A), proxy filed April 19, 2024 |
| Geode Capital | 1,636,722 | 1.99% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 82,280,827 shares outstanding, as reported by BEAM THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BEAM THERAPEUTICS INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 266 asset managers reported votes on at least one of its 3 ballot items in their SEC Form N-PX filings, covering 1,026 separate fund positions. On the most widely held item on that ballot — Approve, on an advisory basis, the compensation of our named executive officers. — BEAM THERAPEUTICS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BEAM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BEAM THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BEAM THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “BEAM THERAPEUTICS (BEAM) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/beam-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.